securities and exchange commissionpdf.secdatabase.com/2281/0001104659-15-071508.pdf · item 9.01...

Business Address80 W. LANCASTER AVENUESUITE 300DEVON PA 19333484-581-7505

Mailing Address80 W. LANCASTER AVENUESUITE 300DEVON PA 19333

SECURITIES AND EXCHANGE COMMISSION

FORM 8-KCurrent report filing

Filing Date: 2015-10-20 | Period of Report: 2015-10-20SEC Accession No. 0001104659-15-071508

(HTML Version on secdatabase.com)

FILERZynerba Pharmaceuticals, Inc.CIK:1621443| IRS No.: 260389433 | State of Incorp.:DE | Fiscal Year End: 1231Type: 8-K | Act: 34 | File No.: 001-37526 | Film No.: 151165417SIC: 2834 Pharmaceutical preparations

Copyright © 2015 www.secdatabase.com. All Rights Reserved.Please Consider the Environment Before Printing This Document

http://www.sec.gov/Archives/edgar/data/0001621443/000110465915071508/0001104659-15-071508-index.htm

http://edgar.secdatabase.com/2281/110465915071508/filing-main.htm

http://www.secdatabase.com/CIK/1621443

http://www.secdatabase.com/CIK/1621443

http://www.secdatabase.com/FileNumber/137526

http://www.secdatabase.com/SIC/2834

http://www.secdatabase.com

SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549

FORM 8-K

CURRENT REPORTPURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): October 20, 2015

ZYNERBA PHARMACEUTICALS, INC.(Exact Name of Issuer as Specified in Charter)

Delaware 001-37526 26-0389433(State or Other Jurisdiction ofIncorporation or Organization)

(CommissionFile Number)

(I.R.S. EmployerIdentification Number)

80 W. Lancaster Avenue, Suite 300Devon, PA 19333

(Address of Principal Executive Offices)

(484) 581-7505(Registrant�s Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under anyof the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act



Item 7.01 Regulation FD Disclosure

On October 20, 2015, Zynerba Pharmaceuticals, Inc. (the �Company�) issued a press release announcing the initiation of aPhase 1 clinical trial for its ZYN002 cannabidiol gel. A copy of this press release is attached hereto as Exhibit 99.1.

Attached as Exhibit 99.2 and furnished for purposes of Regulation FD is a presentation the Company will use at the BioInvestor Forum on October 20, 2015, at 8:30 a.m. PT, and may use from time to time in other presentations or discussions withinvestors, analysts and other parties. A live webcast of the presentation may be accessed through the following linkhttp://www.veracast.com/webcasts/bio/investorforum2015/86102126746.cfm or via the Company�s website (www.zynerba.com) byselecting �Investor Relations� then �News and Events� followed by �Webcast.�

The information in this Item 7.01 (including Exhibits 99.1 and 99.2) is being furnished solely to satisfy the requirements ofRegulation FD and shall not be deemed to be �filed� for purposes of Section 18 of the Securities Exchange Act of 1934 (the �ExchangeAct�) or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference in any filing under theSecurities Act of 1933 or the Exchange Act.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

EXHIBIT

NO. DESCRIPTION

99.1 Press Release, dated October 20, 2015.99.2 Zynerba Pharmaceuticals, Inc. Presentation.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalfby the undersigned hereunto duly authorized.

ZYNERBA PHARMACEUTICALS, INC.

Date: October 20, 2015 By: /s/ Suzanne HanlonName: Suzanne HanlonTitle: Secretary, General Counsel and Vice President,

Human Resources

3

EXHIBIT INDEX



EXHIBIT

NO. DESCRIPTION

99.1 Press Release, dated October 20, 2015.99.2 Zynerba Pharmaceuticals, Inc. Presentation.

4



Exhibit 99.1

Zynerba Pharmaceuticals Initiates Phase 1 Clinical Trial for ZYN002 CBD Gel

First and only patent-protected synthetic CBD gelbeing studied in refractory epilepsy, Fragile X syndrome and osteoarthritis

DEVON, PA, October 20, 2015 � Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), a specialty pharmaceutical company dedicated tothe development of innovative transdermal synthetic cannabinoid treatments, today announced the initiation of a Phase 1 clinical trialfor its ZYN002 cannabidiol (CBD) gel. The �Single Rising Dose Study in Normal Subjects and Patients with Epilepsy� study willevaluate the pharmacokinetic profile and tolerability of ZYN002 in 32 healthy volunteers and then in 12 patients with epilepsy. The firstgroup of healthy volunteers was dosed today in Australia. Results are expected in the first half of 2016.

�The initiation of the ZYN002 CBD Gel Phase 1 trial is an important development milestone for Zynerba,� said Armando Anido,Chairman and CEO of Zynerba Pharmaceuticals. �We believe our novel, highly innovative and proprietary transdermal gel may offerunique advantages by delivering drug through the skin and into the bloodstream. Transdermal delivery of CBD not only avoids first-pass metabolism but it also avoids potential degradation of CBD into THC in the stomach and the associated increased psychoactiveeffects of THC. ZYN002 CBD gel presents significant promise for large unmet patient populations.�

About ZYN002 CBD Gel

Zynerba�s ZYN002 CBD Gel is the first and only synthetic CBD formulated as a patent-protected permeation-enhanced gel and isbeing studied in refractory epilepsy, Fragile X syndrome and osteoarthritis. ZYN002 is a clear, odorless, permeation-enhanced gel thatis designed to provide consistent, controlled drug delivery transdermally with convenient once- or twice-daily dosing. Transdermaltherapeutics are absorbed through the skin directly into the systemic circulation, avoiding first-pass liver metabolism and potentiallyenabling lower dosage levels of active pharmaceutical ingredients and rapid and reliable absorption with high bioavailability. Inaddition, transdermal delivery avoids the gastrointestinal tract and potential stomach acid degradation of CBD into THC, asdemonstrated in a Zynerba in vitro study, which may lead to increased psychoactive effects.

1

About Epilepsy

Epilepsy is a disease characterized by an enduring predisposition to generate epileptic seizures (transient symptoms due to abnormalneuronal activity in the brain) and by the neurobiological, cognitive, psychological and social consequences of the condition. Complexpartial seizures usually start in a small area of the temporal lobe or frontal lobe of the brain and quickly involve other areas of the brainthat affect alertness and awareness. Approximately 2.2 million patients in the United States and 3.1 in Europe and Japan battle epilepsy.Complex partial seizures are the most common type of seizure, representing 35% of all epilepsies.

About Zynerba Pharmaceuticals



Zynerba Pharmaceuticals (NASDAQ: ZYNE) is a specialty pharmaceutical company focused on developing and commercializingproprietary next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Zynerba is developing therapeuticcandidates based on proprietary transdermal technologies that, if successfully developed, may allow sustained, consistent and controlleddelivery of therapeutic levels of two cannabinoids: cannabidiol (CBD), a non-psychoactive cannabinoid, and THC. Transdermaldelivery has the potential to reduce adverse effects associated with oral dosing. ZYN002, the Company�s CBD Gel, is the first and onlysynthetic CBD formulated as a patent protected permeation-enhanced gel and is being studied in refractory epilepsy, Fragile Xsyndrome and osteoarthritis. Zynerba is also developing ZYN001, which utilizes a synthetically manufactured pro-drug of THC in atransdermal patch to deliver THC through the skin and into the bloodstream. ZYN001 will be studied in fibromyalgia and peripheralneuropathic pain. Learn more at www.zynerba.com and follow the company on Twitter at @ZynerbaPharma.

Investor Contacts

Armando Anido, Chairman and CEORichard Baron, CFOZynerba Pharmaceuticals484.581.7505

Media Contact

Jennifer GuinanSage Strategic [email protected]

2

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Wemay, in some cases, use terms such as �predicts,� �believes,� �potential,� �proposed,� �continue,� �estimates,� �anticipates,��expects,� �plans,� �intends,� �may,� �could,� �might,� �will,� �should� or other words that convey uncertainty of future events oroutcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks anduncertainties that may cause actual events or results to differ materially from the Company�s current expectations. For example, therecan be no guarantee that the Company will obtain approval for ZYN002 or ZYN001 from the U.S. Food and Drug Administration(�FDA�) or foreign regulatory authorities; even if ZYN002 or ZYN001 are approved, the Company may not be able to obtain the labelclaims that it is seeking from the FDA. Management�s expectations and, therefore, any forward-looking statements in this press releasecould also be affected by risks and uncertainties relating to a number of other factors, including the following: the success, cost andtiming of the Company�s product development activities, studies and clinical trials; the success of competing products that are orbecome available; the Company�s ability to commercialize its product candidates; the size and growth potential of the markets for theCompany�s product candidates, and the Company�s ability to service those markets; the Company�s ability to develop sales andmarketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of the Company�sproduct candidates; and the Company�s expectations regarding its ability to obtain and adequately maintain sufficient intellectualproperty protection for its product candidates. These and other risks are described under the heading �Risk Factors� the registrationstatement on Form S-1 (commission file number 333-205355), which was declared effective by the Securities and ExchangeCommission on August 4, 2015. Any forward-looking statements that the Company makes in this press release speak only as of the dateof this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information,future events or otherwise, after the date of this press release.



3



Exhibit 99.2

October 2015

Disclaimer The statements in this presentation may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements, among other things relate to the future operations, opportunities or financial performance of Zynerba Pharmaceuticals, Inc. We may, in some cases, use terms such as �predicts,� �believes,� �potential,� �proposed,� �continue,� �estimates,� �anticipates,� �expects,� �plans,� �intends,� �may,� �could,� �might,� �will,� �should� or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company�s current expectations. These and other risks are described in our filings with the Securities and Exchange Commission, available at www.sec.gov. Any forward-looking statements that the Company makes in this presentation speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this presentation. 2 © 2015 Zynerba Pharmaceuticals, Inc. All rights reserved. Zynerba is a trademark of Zynerba Pharmaceuticals, Inc. All other trademarks and registered trademarks are property of their respective owners.



Zynerba Highlights 3 We are the first and only company developing patent-protected synthetic cannabinoid therapeutics for transdermal delivery Management track record of success in patch and gel transdermal delivery, regulatory approval and commercialization Two proprietary product candidates intended to treat diseases with significant unmet medical need and market potential CBD Gel � ZYN002: refractory epilepsy, Fragile X syndrome (FXS) and osteoarthritis (OA) THC Pro-Drug Patch � ZYN001: fibromyalgia and peripheral neuropathic pain IPO August 2015 (NASDAQ: ZYNE) raised $48MM



Proven Leadership in Transdermal Drug Development 4 Armando Anido Chairman of the Board & Chief Executive Officer Terri Sebree President Richard A. Baron VP & Chief Financial Officer Donna Gutterman, PharmD VP, Medical Brian Boyd VP, Manufacturing



Jacqueline French, MD Professor of Neurology, NYU Langone Medical Center John Messenheimer, MD Consultant, Neurologist/Epileptologist, John Messenheimer PLLC Michael Rogawski, MD, PhD Professor of Neurology, UC Davis Center for Neuroscience Rodney Radtke, MD Professor of Neurology, Duke University Medical Center Randi J. Hagerman, MD Medical Director, UC Davis MIND Institute, Distinguished Professor, Endowed Chair in Fragile X Research, Department of Pediatrics, UC Davis School of Medicine Steven J. Siegel, MD, PhD Professor of Psychiatry, University of Pennsylvania, Perleman School of Medicine; Director, Translational Neuroscience Program Daniel Clauw, MD Professor of Anesthesiology, Medicine (Rheumatology) and Psychiatry, University of Michigan Philip Mease, MD Clinical Professor, University of Washington, Seattle; Director of Rheumatology Research, Swedish Medical Center Lesley Arnold, MD Professor of Psychiatry and Behavioral Neuroscience, University of Cincinnati Donald Abrams, MD Professor of Clinical Medicine, University of California San Francisco School of Medicine; Chief of Hematology/Oncology, San Francisco General Hospital Miroslav Backonja, MD Clinical Professor, University of Wisconsin School of Medicine and Public Health; Medical Director, CRILifetree Mark Wallace, MD Professor of Clinical Anesthesia, University of California San Diego Scientific Advisory Board 5 Epilepsy Fragile X Syndrome Osteoarthritis and Fibromyalgia Pain Area

of Expertise



CBD Gel � ZYN002 THC Pro-Drug Patch � ZYN001 Cannabinoid Cannabidiol (CBD) Δ9-Tetrahydrocannabinol (THC) Delivery Permeation-enhanced gel Transdermal patch Activity Non-psychoactive, decreases neuronal hyperexcitability, multiple mechanisms Psychoactive, antinociceptive, agonist of CB1 and CB2 receptors Safety Well characterized with a high therapeutic index Non-mutagenic and non-genotoxic in preclinical studies Delivering CBD transdermally avoids first-pass metabolism and may reduce adverse events by bypassing gastric degradation of CBD to THC Well characterized with a high therapeutic index Non-mutagenic or non-genotoxic in preclinical studies Delivering THC transdermally avoids first-pass metabolism and may reduce psychotropic adverse events Initial Proposed Indications Refractory epilepsy Fragile X syndrome Osteoarthritis Fibromyalgia Peripheral neuropathic pain Patent Protection 2030 2031 Zynerba�s Synthetic Cannabinoids ZYN002 � Proprietary synthetic CBD formulated for delivery via a permeation-enhanced gel ZYN001 � Proprietary synthetic pro-drug of Δ9-THC formulated for delivery via transdermal patch These patent-protected product candidates of fer Zynerba multiple shots on goal 6



CBD Gel � ZYN002 First and only patent-protected permeation-enhanced synthetic cannabidiol gel formulated for transdermal delivery The permeation enhancer in ZYN002 increases the delivery of CBD through the layers of the skin and into the circulatory system 7 CBD Delivery



Potential Benefits of ZYN002 Simple dosage form More consistent, controlled delivery with less frequent dosing (1-2 times daily) Avoids first-pass metabolism and GI degradation of CBD to THC, potentially fewer drug-drug interactions and lower incidence of psychoactive side effects CBD Gel � ZYN002 8 Δ8-tetrahydrocannabinol (Δ8-THC) Δ9-tetrahydrocannabinol (Δ9-THC) Cannabidiol (CBD) 0.1M HCl 0.1M HCl in vitro Study CBD degraded to THC in simulated gastric fluid Up to 10% of CBD degraded to THC within 3 hours May lead to increased psychoactive effects from THC Transdermal delivery of ZYN002 avoids the GI tract, maintains CBD at physiological pH and prevents degradation of CBD to THC



Anticonvulsant effects of CBD have been demonstrated in multiple in vivo and in vitro models of epilepsy Third-party clinical trial showed significant response vs. placebo 88% of the CBD-treated group had a response to treatment 50% of patients had considerable improvement Third-party open-label trial with botanical CBD to assess safety and dosing in treatment-resistant epilepsy (mostly Dravet and Lennox-Gastaut syndrome) showed the median reduction in the number of seizures was 54% at week 12 In a 2013 survey of parents of children with treatment resistant epilepsy , 84% reported a reduction in seizure frequency while taking cannabidiol-enriched Cannabis ZYN002 � Why We Believe it Will Work in Refractory Epilepsy 9



ZYN002 � Why We Believe it Will Work in Fragile X Syndrome 10 Fragile X Syndrome Most common inherited intellectual disability Autism spectrum disorder Behavioral and learning challenges Psychiatric and neurological complications Caused by a mutation in the Fragile X Mental Retardation gene (FMR1) located on the X chromosome Silences FMR1 gene which codes for fragile X mental retardation protein (FMRP) No/low expression FMRP leads to reduction 2-AG, negatively af fecting synaptic function, plasticity & neuronal connections CBD may effectively treat FXS In mouse knock-out model, inhibition of fatty acid amide hydroxylase (FAAH) improves FXS symptoms CBD inhibits FAAH, thereby increasing 2-AG and anandamide concentrations to modulate neurotransmitter release Restores endogenous stimulation of endocannabinoid receptors



ZYN002 � Why We Believe it Will Work in Osteoarthritis 11 Results Significant reductions in: Swelling of knee joints Immune cell infiltration Spontaneous pain rating scores Dose-dependent reduction of pro-inflammatory markers (CD11b/c, CGRP, TNF) in spinal cord and dorsal root ganglia Methods CBD gel was applied for four days after inducing arthritis in rats Knee joint circumference and histology for immune cells were measured to determine level of inflammation Plasma CBD concentration measured Preclinical Data - Animal Model of Inflammatory Pain (OA and RA) CBD Gel � ZYN002 Dose (mg/day) Plasma Concentrations (ng/mL) 0.6 3.8 ± 1.4 3.1 17.5 ± 4.4 6.2 33.3 ± 9.7 62.3 1629.9 ± 379.0



ZYN002 � Why We Believe it Will Work in Osteoarthritis continued 12 Several pre-clinical studies demonstrate the efficacy of cannabinoids for inflammation and pain in animal models for OA/RA In a third-party placebo-controlled study of 58 subjects with rheumatoid arthritis, botanical CBD/THC combination showed significant improvement at 5 weeks in: Pain on movement Pain at rest Sleep quality Disease Activity Score (DAS- 28) and Short Form McGill Pain Questionnaire



CBD Gel � ZYN002 Status in vivo studies in guinea pig, rat, porcine and primate Sustained plasma levels obtained in all species CBD plasma concentration linear in relationship to dose No skin irritation Pre-IND meeting 1Q 2015 First cohort dosed 10/20/15 in Single Rising Dose Phase 1 Study Results 1H2016 13 Note: Subject to change due to further regulatory, clinical and other considerations.



CBD Gel � ZYN002 Phase 1 Clinical Plan 14 Note: Subject to change due to further regulatory, clinical and other considerations. Study Patients Dosing PD Evaluations Single Rising Dose Study in Normal Subjects and Patients with Epilepsy Pharmacokinetic profile and tolerability evaluation 32 healthy volunteers and 12 epilepsy patients (partial onset seizures) Single dose Cognition and visual attention (Trail Making) Multiple Rising Dose Study in Normal Subjects and Patients with Epilepsy Multi-dose pharmacokinetic/ pharmacodynamics profile and tolerability evaluation 16 healthy volunteers and 12 epilepsy patients (partial onset seizures) Dosing for seven days Cognition and attention (Trail Making, PASAT, and Divided Attention); mood (PANAS); subjective drug effects (ACRI) Bioequivalence Study Evaluation of different applications sites � upper arm vs. thigh vs. back 24 healthy volunteers Single dose N/A



CBD Gel � ZYN002 Phase 2 Clinical Plan 15 Note: Subject to change due to further regulatory, clinical and other considerations. Study Patients Dosing Primary Endpoint Efficacy and Tolerability in Patients with Refractory Epilepsy Adjunctive therapy, double-blind, placebo-controlled 80 -120 patients 12 weeks Median percentage change in seizure frequency over the treatment period Efficacy and Tolerability in Patients with Fragile X Syndrome Open label 10 - 20 patients 12 weeks Change in Clinical Global Impression-Improvement (CGI-I) Efficacy and Tolerability in Patients with Osteoarthritis Double-blind, placebo-controlled 80 -120 patients 12 weeks Change from baseline in weekly mean 24-hour average pain score



CBD Gel � ZYN002 Initial Market Opportunity 16 Refractory Epilepsy Fragile X Syndrome Osteoarthritis 2012 US Market Size* (# of Patients) 2.2 million 71,000 Potential for orphan drug designation** 129.5 million 2012 EU and Japan* Market Size (# of Patients) 3.1 million 88,542 147.2 million * Except for FXS data, based on data provided by Decision Resources. Data for epilepsy represents market for all types of epilepsy. FXS data based on 2012 U.S. Census data, The World Bank data, and data provided by the National Fragile X Foundation. ** Fragile X syndrome may qualify for an orphan drug designation in the US because the number of patients in the US with Fragile X syndrome is less than 200,000. Zynerba requested orphan from the FDA in early July.



THC Pro-Drug Patch � ZYN001 17 Patent-protected synthetic D-glyceric acid ester-Δ9-tetrahydrocannabinol in a transdermal patch ZYN001 is a pro-drug A drug administered in an inactive or less active form, designed to enable more effective delivery, and then converted into a different form through a normal metabolic process Unlike THC, ZYN001 is able to be efficiently absorbed into the skin through transdermal delivery After crossing the stratum corneum, ZYN001 is hydrolyzed to THC and glyceric acid under physiological conditions Structure & Conversion Delivery ZYN001



Note: Based upon FDA approved patch products. These results are not indicative of any preclinical or clinical data for ZYN001. Why a Patch? 18 Requirement Purpose Non-oral Avoids first-pass metabolism with increased bioavailability and more consistent plasma levels Controlled More consistent, controlled and sustained delivery No �peaks and valleys� as seen with oral Safe Improved safety profile with lower peak plasma levels Non-invasive Blood Level Time Max. Effective Level Min. Effective Level Oral Dosage Form Transdermal System Illustrative Controlled Delivery



Potential Benefits of ZYN001 Once daily dosing Consistent plasma levels, which we believe will deliver therapeutic benefit with minimal psychoactive side effects thereby distinguishing it from oral and oral mucosal delivery systems Avoidance of first-pass liver metabolism and may reduce psychotropic adverse events. THC Pro-Drug Patch � ZYN001 19



THC is a partial agonist of the CB1 and CB2 receptors. CB1 agonists have been shown to have an analgesic effect in chronic pain models. The CB1 agonists act at many sites along pain transmission pathways including activation of peripheral and spinal CB1 receptors Nabilone (an analogue of THC) was demonstrated to be effective for the treatment of fibromyalgia in a randomized, double-blind, placebo-controlled trial conducted by the University of Manitoba 40 subjects with fibromyalgia received nabilone or placebo x 4 weeks Significant decreases in pain score using visual analog scale (VAS), Fibromyalgia Impact Questionnaire (FIQ) and FIQ anxiety score Nabilone demonstrated efficacy in a third-party randomized, double-blind, active controlled cross-over study in fibromyalgia patients with chronic insomnia 29 subjects received nabilone and amitriptyline x 2 weeks with a 2 week washout Nabilone was superior to amitriptyline in sleep quality ZYN001 � Why We Believe it Will Work in Fibromyalgia 20



Third-party randomized, double-blind, placebo-controlled crossover trial in diabetic peripheral neuropathy (DPN) demonstrated that THC is effective in reducing neuropathic pain 16 patients with DPN received low (1% THC), medium (4% THC), high (7% THC) dose vaporized Cannabis and placebo in randomized crossover design Pain scores, cognitive effects and tolerability were assessed All THC doses were significantly better than placebo in reducing spontaneous pain The high dose THC (7%) impaired performance on 2 of 3 neuropsychological tests Several third-party placebo controlled trials of vaporized cannabis, smoked cannabis and cannabis via an inhaler have demonstrated efficacy in peripheral neuropathic pain. ZYN001 � Why We Believe it Will Work in Peripheral Neuropathic Pain 21



THC Pro-Drug Patch � ZYN001 Demonstrates Sustained, Consistent Delivery 22 Pharmacokinetics in Guinea Pigs Removed patches at 72 hours 0



THC Pro-Drug Patch � ZYN001 Status FDA pre-IND meeting completed August 2013 in vitro and in vivo studies Effective skin permeation with sustained delivery Non-mutagenic and non-genotoxic Safety pharmacology GLP studies Profile similar to THC GLP toxicology studies ongoing Expected Phase 1 to be initiated mid-2016 23 Note: Subject to change due to further regulatory, clinical and other considerations.



THC Pro-Drug Patch � ZYN001 Preliminary Phase 1 Clinical Plan 24 Study Patients Dosing PD Evaluations Single Rising Dose Study in Normal Subjects Pharmacokinetic profile and tolerability evaluation 32 healthy volunteers and 12 patients with peripheral neuropathic pain Single dose Cognition and attention (Trail Making, PASAT, and Divided Attention); mood (PANAS); subjective drug effects (ACRI) Multiple Rising Dose Study in Normal Subjects and Patients with Fibromyalgia Multi-dose pharmacokinetic/ pharmacodynamic profile and tolerability evaluation 16 healthy volunteers and 12 patients with peripheral neuropathic pain Dosing for seven days Capsaicin pain model; cognition and attention (Trail Making, PASAT, and Divided Attention); mood (PANAS); subjective drug effects (ACRI) Bioequivalence Study Evaluation of different application sites � upper arm vs. thigh vs. back 24 healthy volunteers Single dose Bioequivalence at arm, thigh and back



THC Pro-Drug Patch � ZYN001 Preliminary Phase 2 Clinical Plan 25 Note: Subject to change due to further regulatory, clinical and other considerations. Study Patients Dosing Primary Endpoint Efficacy and Tolerability in Patients with Peripheral Neuropathic Pain Double-blind, placebo-controlled 80 - 120 patients 12 weeks Visual Analog Scale for pain intensity Efficacy and Tolerability in Patients with Fibromyalgia Double-blind, placebo-controlled 80 - 120 patients 12 weeks Change from baseline in Fibromyalgia Impact Questionnaire (FIQ) total score



THC Pro-Drug Patch � ZYN001 Initial Market Opportunity 26 Fibromyalgia Peripheral Neuropathic Pain 2012 US Market Size* (# of Patients) 5.6 million 14.0 million 2012 EU and Japan Market Size* (# of Patients) 10.8 million 20.3 million Data provided by Decision Resources.



Expected Development Timelines 27 Asset 2015 2016 2017 THC Pro-Drug Patch � ZYN001 Unpartnered � Zynerba holds global rights Preclinical Phase 1 Fibromyalgia Phase 2a CBD Gel � ZYN002 Preclinical Refractory Epilepsy Fragile X Syndrome Phase 2a Phase 1 Osteoarthritis Phase 1 Peripheral Neuropathic Pain



Zynerba Highlights 28 We are the first and only company developing patent-protected synthetic cannabinoid therapeutics for transdermal delivery Management track record of success in patch and gel transdermal delivery, regulatory approval and commercialization Two proprietary product candidates intended to treat diseases with significant unmet medical need and market potential CBD Gel � ZYN002: refractory epilepsy, Fragile X syndrome (FXS) and osteoarthritis (OA) THC Pro-Drug Patch � ZYN001: fibromyalgia and peripheral neuropathic pain IPO August 2015 (NASDAQ: ZYNE) raised $48MM



Investor Relations 29 NASDAQ: ZYNE Analyst Coverage* Jefferies: Biren Amin, PhD Piper Jaffray: Charles C. Duncan, PhD Canaccord Genuity: Corey Davis, PhD Oppenheimer: Rahit Vanjani, MBA * Note: Any opinions, estimates or forecasts regarding Zynerba Pharmaceuticals, Inc.�s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Zynerba Pharmaceuticals, Inc. or its management. Zynerba Pharmaceuticals, Inc. does not by its reference above imply its endorsement of or concurrence with such information, conclusions or recommendations. 484.581.7505 [email protected] www.zynerba.com @ZynerbaPharma Zynerba Zynerba Investor Contacts Armando Anido, Chairman and CEO Richard Barton, Vice President and CFO



securities and exchange commissionpdf.secdatabase.com/2281/0001104659-15-071508.pdf · item 9.01...

Documents